Soleno Therapeutics (SLNO) announced that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement with Jefferies to repurchase $100 million of Soleno’s common stock.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating
- Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
- Soleno Therapeutics’ Earnings Call Highlights Growth Amid Challenges
- Midday Fly By: Broader market bought on dip after tech selloff
- Soleno Therapeutics falls -29.0%